[Suicidal risk prevention in schizophrenia: Importance of family psychoeducation].

Prévention du risque suicidaire dans la schizophrénie : importance de la psychoéducation des familles.
Behavioral cognitive therapy Family intervention Intervention familiale Prevention Prévention Psychoeducation Psychoéducation Schizophrenia Schizophrénie Suicide Thérapie comportementale et cognitive

Journal

L'Encephale
ISSN: 0013-7006
Titre abrégé: Encephale
Pays: France
ID NLM: 7505643

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 15 06 2019
revised: 03 02 2020
accepted: 07 02 2020
pubmed: 23 4 2020
medline: 25 11 2021
entrez: 23 4 2020
Statut: ppublish

Résumé

Although mortality by suicide in schizophrenia seems to have decreased in some countries over the last 30 years, it remains much higher than in the general population. Studies have shown this risk to impact around 5% of patients, corresponding to a risk almost 2.5 times higher than in the general population. Family psychoeducation in schizophrenia has been demonstrated to lead to symptom reductions and to an improvement of the quality of life, two factors that should contribute to decreasing the suicidal risk. Therefore, if families attend an efficient psychoeducation program, we can expect a decrease in the patient suicidal risk. Attending a family psychoeducation program at the beginning of the disease would also be associated with a stronger preventive effect on suicidal mortality. The objective of this study is to describe the suicide attempt rate of patients who suffer from schizophrenia before and one year after one of their relatives participated to the family psychoeducation program Profamille. We performed a retrospective study on 1209 people who attended the Profamille (V3.2 version) Family Psychoeducation Program. This program has 2 modules: an initial training module of 14 weekly or fortnightly sessions, and a consolidation module of 4 sessions over 2 years. Sessions last 4 hours and follow a precise and structured course. Data were collected from 40 different centers in France, Belgium and Switzerland and were based on participants assessed at the beginning and one year after the first module. Self-assessment from the relatives participating in the program provided the measure of patients' suicide attempts. An assessment at T0 explored the attempts over the 12 months before the beginning of the program while the assessment at T1 analyzed those during the 12 months following the end of the Program. The Chi The number of participants reporting that their relative had attempted suicide in the previous 12 months decreased from 41 to 21. The annual attempts rate was evaluated at 6.4 % before the Profamille program and decreased to 2.4 % a year after the end of the program (P=0.0003). The reduction of the attempt rate was observed even for patients with schizophrenia for more than 10 years. This study shows the positive impact of Profamille on reducing the rate of suicide attempts in patients with schizophrenia. It has been shown that the risk is highest at the beginning of the disorder. Therefore, based on our results, it would seem appropriate to propose the Profamille program at an early stage.

Identifiants

pubmed: 32317163
pii: S0013-7006(20)30039-7
doi: 10.1016/j.encep.2020.02.002
pii:
doi:

Types de publication

Journal Article

Langues

fre

Sous-ensembles de citation

IM

Pagination

450-454

Informations de copyright

Copyright © 2020. Published by Elsevier Masson SAS.

Auteurs

Y Hodé (Y)

Institut de psychiatrie GDR 3557 Paris, 1, rue Cabanis, 75014 Paris, France. Electronic address: yann.hode@yahoo.fr.

J Dubreucq (J)

C3r CH Alpes-Isère, 3, rue de la Gare, 38120 Saint-Égrève, France.

E Valladier (E)

Service hospitalo-universitaire-S14, centre référent en remédiation cognitive et réhabilitation psychosociale (C3RP), centre hospitalier Sainte-Anne, 75014 Paris, France.

N Guillard Bouhet (N)

CREATIV, centre hospitalier H. Laborit, Poitiers, 370, avenue Jacques-Cœur, 86021 Poitiers, France.

S Lemestré (S)

ASBL Similes Wallonie, rue Lairesse, 15, 4020 Liège, Belgique.

J Attal (J)

Service universitaire de psychiatrie adulte, hôpital la Colombière, CHRU Montpellier, 191, avenue du Doyen Gaston-Giraud, 34295 Montpellier cedex 5, France.

O Canceil (O)

Pôle Paris 12 - Secteur 75G10/11 hôpitaux de Saint-Maurice, 12-4, rue du Val d'Osne, 94410 Saint-Maurice, France.

M Biotteau (M)

Département de psychiatrie, CHU de Tours, 37044 Tours cedex 9, France.

P Laffond (P)

Hôpital de Malévoz, route de Morgins, 10, 1870 Monthey, Suisse.

A Raynaud (A)

Filière ambulatoire, centre hospitalier Esquirol, 15, rue Doct Raymond-Marcland, 87000 Limoges, France.

I Chéreau-Boudet (I)

Service de psychiatrie de l'adulte, CHU de Clermont-Ferrand, rue Montalembert, BP 69, 63003 Clermont-Ferrand, France.

A Montagne Larmurier (A)

Service de psychiatrie adulte, CHU de Caen, avenue de la Côte de Nacre CS 30001, 14033 Caen cedex 9, France.

J-Y Giordana (JY)

CHS Sainte-Marie, 87, avenue Joseph-Raybaud, 06200 Nice, France.

B Saingery (B)

EPSM des Ardennes CHS Bélair, 1, rue Pierre-Hallali, 08000 Charleville-Mézières, France.

T d'Amato (T)

SHU pôle est, centre hospitalier Le-Vinatier, BP 30039 - 95, boulevard Pinel, 69678 Bron, France.

D Willard (D)

C3R-P/CJAAD, service hospitalo-universitaire, GHU Paris psychiatrie et neurosciences, 1, rue Cabanis, 75014 Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH